63 results about "Cisplatin resistance" patented technology

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a novel tubulin and metalloproteinase double-target inhibitor as well as a preparation method and application of the novel tubulin and metalloproteinase double-target inhibitor. A novel tubulin and metalloproteinase double-target inhibitor is obtained as a compound with a targeting function. A verification result shows that the synthesized target compound shows good anti-proliferative activity on tested cancer cells, 15j has the optimal anti-tumor activity, the IC50 value range of the target compound is 0.154-0.296 mu M, and the tumor inhibition rate of the target compound on human lung cancer transplantation tumors is 74.7% (20 mg / kg). Besides, the anti-proliferative activity of the 15j to cis-platinum drug-resistant cells A549 / CDDP is 136.70 times that of the cis-platinum, the anti-proliferative activity of the 15j to adriamycin drug-resistant cells MCF-7 / DOX is 71.14 times that of the adriamycin, and the toxicity of the 15j to human normal cells (LO2 and MCF-10A) is lower than that of positive drugs such as the cis-platinum, the adriamycin and the paclitaxel. Therefore, the compound has the potential purpose of targeted treatment of lung cancer.

The application discloses a vanadium-based nano drug capable of reversing cisplatin drug resistance through multiple targets and a preparation method thereof.The preparation method of the drug comprises the following steps: (1) preparation of mesoporous silica; (2) vanadium ion doping; (3) surface amino modification; (4) loading of a Pt(IV) prodrug; and (5) PDGF modification on the surface of the drug-loaded nanoparticles, thereby obtaining the vanadium-based nano drug.The vanadium-based nano drug prepared by the method has excellent performance, can reverse cisplatin drug resistance through multiple targets, and provides a new idea for constructing a lung cancer precision treatment scheme for reversing cisplatin drug resistance through multiple targets.

The invention belongs to the technical field of biomedicine, and relates to a human bladder cancer cell line ZSZB1 with primary cis-platinum drug resistance and application thereof. The cell line is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC No: C2024120, and the cell line is derived from a radical operation specimen of primary chemotherapy drug-resistant bladder cancer patients of Chinese population, and has stable in-vitro multiplication capacity and primary cis-platinum drug-resistant characteristic. The ZSZB1 provides an ideal experimental model for bladder cancer pathogenesis research, cis-platinum drug resistance mechanism exploration and novel antitumor drug screening. Establishment of the cell line can effectively promote transformation from basic research of bladder cancer to clinical application, and the cell line is of great significance to promotion of precise medical development.

The invention discloses application of a small molecule compound in preparation of a medicine for treating ovarian cancer, and belongs to the technical field of biological medicine. The small molecule compound comprises a structure as shown in a formula (I) or an isomer, a pharmaceutically acceptable solvate or salt thereof, it is found for the first time that the small molecule compound can effectively reduce protein expression of YBX1, and meanwhile in-vitro verification experiments prove that the small molecule compound has a remarkable inhibition effect on proliferation of ovarian cancer cells. In addition, it is found that the small molecule compound can improve the cytotoxicity of cis-platinum and significantly enhance the anti-tumor effect of cis-platinum. The application of the small molecule compound YB-B1 targeting YBX1 in preparation of the medicine for treating the ovarian cancer is disclosed for the first time, a new method and a new idea are provided for clinical treatment of the ovarian cancer, and the small molecule compound YB-B1 particularly has remarkable significance in auxiliary treatment and prevention and treatment of cis-platinum drug-resistant ovarian cancer.

The invention discloses an antibody for specifically recognizing 1147th acetylation of ribosome biosynthetic factor 1 protein as well as a preparation method and application of the antibody. According to the protein sequence and the modification type of the ribosome biosynthetic factor 1, two modified antigen polypeptides A and B are designed, and through detection, the antibody obtained by immunizing animals with the two polypeptides has high specificity and affinity, can accurately recognize the acetylation modification form of the 1147th site of BMS1, and avoids recognition of an unmodified form or other modification sites. The antibody is suitable for various immunological detection methods, is high in repeatability and low in background, has mass production potential, can realize industrialization, not only can be used for evaluating the cis-platinum drug resistance condition in esophageal cancer treatment, but also can be used for various scenes such as basic research, disease mechanism analysis, biomarker development and drug target screening, and is wide in application range.

The invention discloses a ruthenium complex for inducing mitochondrial DNA polycondensation to overcome tumor drug resistance, an anti-tumor drug and a preparation method and application of the ruthenium complex and the anti-tumor drug. The ruthenium complex is connected with a triphenylphosphine structure-modified bipyridine diazo-anthracene ligand through an alkyl chain, so that the fat solubility of the complex is improved, and the complex can enter cells more easily; the complex has a mitochondrial enrichment function and can be enriched in mitochondria; the complex induces mitochondrial DNA polycondensation so as to cause cancer cell death; the targeting property on tumor cells is effectively improved; the IC50 of the compound on human non-small cell lung cancer cell strains and cis-platinum drug-resistant strains thereof is far lower than that of cis-platinum, and the compound can be used as an excellent anti-tumor drug. The complex takes a ruthenium-coordinated ruthenium precursor compound as a raw material, and the raw material is economical and easy to obtain; the selectivity of the ruthenium complex can be improved, and the cost is saved.

The invention discloses application of a copper carrier in a medicine for enhancing drug resistance of copper death reversing liver cancer cells, and relates to the technical field of medicines. The copper carrier provided by the invention can activate copper death in cisplatin-resistant liver cancer cells in a manner of'three-arrow simultaneous shooting '. The method mainly comprises the following steps: increasing the number of copper ions entering cells (a first'arrow '), consuming GSH to reduce the loss of copper ions in the cells (a second'arrow'), and down-regulating the expression of ATP7B to inhibit the outflow of copper ions (a third'arrow '). Besides, the copper carrier down-regulates copper death related proteins (FDX1, DLAT, ATP7B and LIAS), also down-regulates drug resistance related proteins (ATP7B and P-gp), and shows a remarkable anti-liver cancer curative effect. Particularly, the bCCM can target mitochondria, improve the mitochondrial copper ion level, consume mitochondrial GSH and cause mitochondrial dysfunction mediated by copper death, and the bCCM and the cis-platinum have a remarkable synergistic effect and can reverse the drug resistance of the cis-platinum.

The invention relates to application of an antibody for detecting phosphorylation of a Tyr165 site of CPT1A protein in preparation of a product for detecting the sensitivity of head and neck squamous cell carcinoma to cis-platinum. The CPT1A protein Tyr165 site is obtained through cisplatin stress and phosphorylation mass spectrometry identification, the phosphorylation level of the CPT1A protein Tyr165 site is increased along with the increase of cisplatin stress time, and the drug resistance degree of the head and neck squamous cell carcinoma to cisplatin is enhanced. Therefore, the CPT1A protein Tyr165 site is phosphorylated to serve as the biomarker of the cis-platinum drug resistance of the head and neck squamous cell carcinoma. The invention further provides a specific antibody for phosphorylation of the Tyr165 site of the CPT1A protein, the antibody is used for detecting whether the Tyr165 site of the CPT1A protein is phosphorylated or not, whether the head and neck squamous cell carcinoma has drug resistance to cis-platinum or not is determined, and a basis is provided for targeted selection of chemotherapeutic drugs for the head and neck squamous cell carcinoma.

The invention discloses application of DNASE1L3, CYP4B1 and / or FAM65B in enhancing the cisplatin sensitivity of nasopharyngeal carcinoma, and belongs to the field of biological medicine. The invention proves that overexpression of the DNASE1L3 gene, the CYP4B1 gene and / or the FAM65B gene can obviously inhibit the activity of nasopharyngeal carcinoma cells and obviously enhance the sensitivity of the nasopharyngeal carcinoma cells to cis-platinum. An in-vivo xenotransplantation tumor model further proves that the in-vivo anti-tumor effect of the cis-platinum can be remarkably enhanced by combining the overexpressed DNASE1L3 gene, the CYP4B1 gene or the FAM65B gene with the cis-platinum, and tumor growth is effectively inhibited. The invention provides a brand new molecular target for overcoming the cisplatin resistance of nasopharynx cancer, provides a new strategy for preparing high-efficiency and low-toxicity nasopharynx cancer treatment drugs and cisplatin sensitizers, and has important clinical application prospects and market values.

The invention relates to the field of medicinal chemistry, in particular to a substituted benzenesulfonamide compound and application thereof. Pharmacological experiment results show that the benzenesulfonamide compounds have strong inhibitory activity on GSTP1-1 protein, and part of the compounds have anti-proliferation effects on tumor cells of human lung cancer, cis-platinum drug-resistant lung cancer and the like, and have a certain degree of cis-platinum drug resistance reversing capability.

The invention belongs to the field of medicines, and discloses a pharmaceutical composition for inhibiting the growth of cisplatin-resistant tumors, which comprises a TGFR2 inhibitor, a PD-1 antibody and auxiliary components, and the auxiliary components are 2-amino-2-norbornic acid and / or 4-methylumbelliferone. The composition can effectively relieve the growth of the positive drug-resistant tumor of the Pars2 caused by cis-platinum, and experiments prove that the TGFR2 inhibitor, the PD-1 antibody and the auxiliary components have obvious synergy. In addition, the invention also discloses application of the composition.

The invention belongs to the technical field of biological medicine, and particularly discloses a combined tumor marker for noninvasive detection of oral cancer and application of the combined tumor marker. The invention provides application of a reagent for detecting a biomarker in preparation of a product for diagnosing or predicting oral cancer. The biomarker is an RBMX gene and / or an NEK2 gene. The invention finds that the two oral cancer carcinogenic key molecules are significantly highly expressed in oral cancer tissues, and the activity, migration and invasion ability of oral cancer cells can be inhibited by knocking down the expression of RBMX or NEK2, and the cis-platinum drug resistance of the oral cancer cells can be inhibited. According to the invention, RBMX or NEK2 is taken as a tumor marker to detect the oral cancer and has good diagnostic efficacy, and the RBMX and the NEK2 are combined for use, so that the sensitivity and the specificity of diagnosis can be further improved, and the risk of the oral cancer can be more comprehensively judged. The invention also provides application of the two pathogenic factors as inhibition targets in preparation of drugs for oral cancer.

The present invention relates to a composition for the prevention or treatment of cisplatin-resistant cancer comprising an inhibitor of DUSP23 expression or activity as an active ingredient. It was found that DUSP23 expression is upregulated in cell clusters exhibiting characteristics of cancer stem cells, and that knocking down DUSP23 significantly reduces cell cluster formation as well as decreases the expression of SOX2, a major stem cell marker. Furthermore, DUSP23 expression was increased in lung cancer cells that had developed cisplatin resistance, and it was confirmed that the downregulation of DUSP23 inhibits self-renewal and invasive capabilities during the induction of cancer cell death. In addition, it was confirmed that DUSP23 plays an important role in promoting cancer stem cell characteristics through SOX2 expression. In conclusion, it has been shown that targeting DUSP23 can be a promising therapeutic strategy to overcome anticancer drug resistance in lung cancer, and the composition of the present invention is expected to be usefully utilized as a treatment for lung cancer cells with cisplatin resistance.

The invention discloses a preparation method and application of a nasal administration compound preparation for relieving the drug resistance of cisplatin, belongs to the field of precision medicine, and particularly relates to the nasal administration compound preparation for relieving the drug resistance of cisplatin. Comprising stem cell exosome, zanthoxylum polysaccharide, cis-platinum and normal saline, the stem cell exosome is a human adipose-derived stem cell exosome; the concentration of the human adipose-derived stem cell exosome is (2-5) * 10 < 7 > parts / mL. The nasal delivery compound preparation for relieving the cisplatin resistance has the advantages that the exosome is low in cytotoxicity and good in anti-tumor activity, the E2F8 / PDK1 axis can be adjusted, the cisplatin resistance of lung adenocarcinoma cells can be weakened, the lung adenocarcinoma cells can be effectively killed, the good lung adenocarcinoma treatment effect of the nasal delivery compound preparation is reflected, and the application prospect is wide. The compound is expected to be applied to development and use of medicines for clinically treating lung adenocarcinoma.

The invention provides a novel human distal bile duct cancer cell line with TP53 missense mutation and application, the novel human distal bile duct cancer cell line CBC3T-3 is established, the cell line is preserved in the China Center for Type Culture Collection (the preservation number is CCTCC NO: C202555), the uniqueness and stability of the cell line are proved through STR typing and karyotype analysis, and the TP53 missense mutation novel human distal bile duct cancer cell line has the advantages that the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3 can be used for preparing the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3; and a plurality of driver gene mutations including TP53 missense mutation are carried. The CBC3T-3 has strong proliferation, invasion and migration capabilities, has high tumor formation rate in immunodeficient mice, is resistant to cis-platinum and sensitive to paclitaxel and gemcitabine, and provides an experimental basis for selection of clinical chemotherapy regimens. According to the model, the TP53 missense mutation type distal bile duct cancer in-vitro model is successfully established, and a key experimental platform is provided for deeply researching the drug resistance mechanism of the TP53 missense mutation type distal bile duct cancer and developing an individualized treatment strategy aiming at the subtype of the TP53 missense mutation type distal bile duct cancer.

The invention discloses a gold (I) complex containing an alkyne ligand, a preparation method of the gold (I) complex and application of the gold (I) complex in preparation of antitumor drugs, the gold (I) complex has a structure as shown in a general formula I, a phosphorus ligand is selected from diphenyl-2-pyridine phosphine or tricyclohexylphosphine, and Rx is an organic group selected from a specific alkyne ligand; according to the preparation method, chloroauric acid is taken as an initial raw material, sequentially reacts with dimethyl sulfide and an organic phosphine ligand, and finally is coupled with an alkyne ligand under an alkaline condition, so that the steps are simple and convenient, the conditions are mild, and the yield is high; in-vitro activity experiments show that the complex shows remarkable proliferation inhibition activity on ovarian cancer, malignant melanoma, non-small cell lung cancer and cisplatin-resistant cell strains thereof, the effect of the complex is superior to that of cisplatin and auronafine, and a candidate compound is provided for developing a novel targeted anti-tumor drug for overcoming the drug resistance of platinum drugs.

Pediatric liver cancers (PLC) are rare tumors. In particular, hepatoblastomas are usually treated with cisplatin-based neoadjuvant chemotherapy followed by surgical removal of the tumor and adjuvant chemotherapy. However, some hepatoblastomas develop resistance to chemotherapy during the initial neoadjuvant chemotherapy or after tumor recurrence, and the molecular determinants of cisplatin resistance are yet to be discovered. In contrast to hepatoblastomas, pediatric HCCs respond poorly to chemotherapy, and as in adults, they have a poor prognosis if not completely removed by surgery. There is thus an urgent need for new therapeutic strategies to overcome this resistance. Now the inventors demonstrate that Elimusertib and Cisplatin combination shows synergistic efficacy on tumor cell viability inhibition in pediatric liver cancer cell lines. The present invention thus relates to the combination of cisplatin and Elimusertib for the treatment of pediatric liver cancers.

The application discloses application of an alkaloid derivative or a medicinal salt thereof in preparation of a medicine for resisting non-small cell lung cancer cisplatin resistance, and a structure of the alkaloid derivative is as follows: The application finds that compound A45 can induce K48 connection type polyubiquitination of TNKS, and is degraded through a proteasome pathway, triggers a DNA damage response, activates a p53 pathway, and induces autophagic cell death, so that a specific action mechanism is achieved to achieve a treatment effect of resisting non-small cell lung cancer cisplatin resistance. Therefore, the compound A45 can be used as a candidate compound for the non-small cell lung cancer cisplatin resistance, a major treatment dilemma, has important development prospects and clinical application value, and provides a scientific basis and an experimental basis for development of an antitumor effect of other Aaptamine alkaloid derivatives and exploration of a strategy for overcoming the non-small cell lung cancer cisplatin resistance.

The invention belongs to the technical field of biological medicines, and particularly discloses a nano-drug for oral cancer as well as a preparation method and application of the nano-drug. The nano-drug provided by the invention is a drug-loaded mesoporous polydopamine nano-particle wrapped by a lipidosome modified by RGD peptide; wherein the load components of the mesoporous polydopamine nanoparticles comprise a cis-platinum drug and an RBMX gene expression inhibitor. The molecular RBMX related to regulation and control of oral cancer progress and cis-platinum drug resistance is screened, a nano biomimetic material drug loading system is constructed to load si-RBMX and cis-platinum to synergistically resist oral cancer treatment, and a novel nano drug with strong targeting property, good biological safety and excellent tumor lethality is obtained. The invention also provides a preparation method and application of the nano-drug.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a miR-21 inhibitor loaded and iRGD peptide modified 293T cell exosome and a method for treating osteosarcoma cis-platinum resistance based on the modified 293T cell source exosome and combining with the miR-21 inhibitor. The miR-21 inhibitor is loaded into the exosome by using an electroporation technology, tumor cells are accurately targeted, activation of ferroptosis signal channels is promoted, the treatment effect of cis-platinum is remarkably enhanced, and the drug resistance of cis-platinum is overcome. The technology provides a novel drug delivery platform for precise treatment of osteosarcoma.

The invention belongs to the technical field of tumor drug research, and particularly relates to application of 2-phenyl oxindole in preparation of a drug for reversing cis-platinum drug resistance or treating tumors. In-vitro experiments and in-vivo experiments prove that the 2-phenyl oxoindole can effectively inhibit proliferation of triple negative breast cancer cells and can remarkably improve the sensitivity of the cells to cis-platinum with a series of concentrations, and pathological staining results of visceral organs and tissues of mice show that the 2-phenyl oxoindole can effectively inhibit proliferation of the triple negative breast cancer cells and remarkably improve the sensitivity of the cells to cis-platinum with a series of concentrations. The 2-phenyl oxoindole does not cause obvious injury to main organs such as liver, kidney and the like.

The present invention discloses a class of divalent platinum complexes containing non-steroidal anti-inflammatory drug structural units, their derivatives, preparation methods, pharmaceutical compositions and applications. The structure of this class of divalent platinum complexes is as follows: The derivatives of this class of divalent platinum complexes refer to isomers of the said divalent platinum complexes or mixtures thereof. When this class of divalent platinum complexes and their derivatives act on cancer cells, they can cause apoptosis by inducing DNA damage and the production of reactive oxygen species, and can also effectively inhibit the growth of cancer cells by down-regulating the expression of cyclooxygenase 2 to reduce inflammation. At the same time, this class of divalent platinum complexes with C=N double bonds can also target tumors using the acidic microenvironment of tumors, reduce tissue toxicity, show the characteristics of high efficiency and low toxicity in anti-tumor, and can overcome cisplatin resistance to a certain extent, and can be prepared into anti-tumor drugs. In addition, the synthesis method of this class of divalent platinum complexes is simple and easy to operate.

The invention discloses a new application of tripterine, namely application of the tripterine in preparation of bladder cancer resisting drugs, in-vitro cell experiments prove that the tripterine shows remarkable proliferation inhibition activity on various bladder cancer cell strains including cell strains UM-UC-3, TCCSUP and T24 and a cis-platinum drug-resistant strain T24CDDP, the median inhibitory concentration (IC50) of the tripterine is 0.2688-0.5870 mu M, and the tripterine shows remarkable proliferation inhibition activity on various bladder cancer cell strains including cell strains UM-UC-3, TCCSUP and T24 and a cis-platinum drug-resistant strain T24CDDP. The further mechanism research shows that the tripterine can regulate and control the cell cycle by down-regulating the expression levels of CDK1 and CDC5L proteins in bladder cancer cells and up-regulating the expression of phosphorylated p53 (p-p53) proteins at the same time, thereby playing a role in resisting bladder cancer; the invention provides a new effective candidate drug for clinical treatment of bladder cancer, especially cis-platinum resistant bladder cancer, and has important clinical application value.

The invention relates to an engineered exosome for targeting bladder cancer cells as well as a preparation method and application of the engineered exosome, and the engineered exosome is specific siRNA (small interfering Ribonucleic Acid) which is subjected to surface modification with concanavalin A and loaded with CASC11, and is marked as ConA-EXO-siCASC11. According to the invention, the engineered exosome is modified by ConA, so that the CASC11-siRNA is effectively delivered to the BLCA cells, the therapeutic effect of the CASC11-siRNA on the BLCA cis-platinum resistance is explored, an emerging therapeutic scheme is provided for the cis-platinum resistance BLCA, and the development of the field of precise treatment based on the engineered exosome is promoted.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a tripterine-platinum (IV) complex with antitumor activity as well as a preparation method and application of the tripterine-platinum (IV) complex. The tripterine-platinum (IV) complex takes tripterine as an axial ligand, and a platinum center skeleton structure is cis-platinum, carboplatin or oxaliplatin. The tetravalent platinum complex can induce para-apoptosis of cancer cells, so that the common problem of drug resistance caused by apoptosis resistance of the cancer cells in tumor chemotherapy is solved. Besides, the tetravalent platinum complex has the characteristics of high efficiency and low toxicity, the in-vitro cytotoxicity of the tetravalent platinum complex to tumor cells such as non-small cell lung cancer A549 cells and cisplatin-resistant strains A549cisR thereof is higher than that of clinically applied metal anti-cancer drug cisplatin, and the tetravalent platinum complex has low toxicity to normal cells MRC-5, so that the tetravalent platinum complex has a good application prospect. Good selectivity and relatively high medicinal value are shown in the aspect of inhibiting the growth of tumor cells.

The present invention relates to the field of medicinal chemistry, specifically to a class of substituted benzenesulfonamide compounds and their applications. Pharmacological experiments have shown that the benzenesulfonamide compounds of the present invention have strong inhibitory activity against GSTP1-1 protein. Some compounds have anti-proliferative effects on tumor cells, including human lung cancer and cisplatin-resistant lung cancer, and have a certain degree of ability to reverse cisplatin resistance.

The present invention belongs to the technical field of pharmaceutical chemistry, and discloses a cisplatin (IV) prodrug with Chuanxiong-chalcone as a ligand, and a preparation method and application thereof. The present invention introduces Chuanxiong-chalcone into the axis of a platinum (IV) complex, prepares a multifunctional platinum (IV) prodrug, and optimizes its structure. Studies have shown that this type of platinum (IV) complex has a significant external anti-tumor value-added effect, especially better than cisplatin in activity against pancreatic cancer cells, but has low toxicity to normal human cells (such as human umbilical vein cell line HUEVC and normal liver cell line L02). At equal doses, the representative product has better anti-tumor effect than cisplatin in a cisplatin-resistant pancreatic cancer transplantation model, but does not show obvious toxic side effects. Therefore, this type of cisplatin (IV) prodrug with Chuanxiong-chalcone as a ligand has a potential use in targeted treatment of pancreatic cancer.

The invention belongs to the technical field of biological medicines, and particularly relates to a human head and neck squamous cell carcinoma cis-platinum and fluorouracil double-drug-resistant cell strain as well as a construction method and application thereof. The invention provides a human head and neck squamous cell carcinoma cis-platinum and fluorouracil double-drug-resistant cell strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.45847, aiming at the problem that a systematic and repeatable model for accurately simulating the clinically observed cis-platinum drug resistance is lacked in the prior art. The invention also provides a construction method and application of the cell strain. The cell strain is constructed by taking human head and neck squamous cell carcinoma cell line SAS as an object and gradually increasing the drug concentration, provides a basis for research of a head and neck squamous cell carcinoma chemotherapy drug resistance mechanism and development of drug resistance related targets, and has an important application value.

The application discloses an antibody capable of specifically recognizing acetylation of ribosome biogenesis factor 1 protein at the 1147th position, and a preparation method and application thereof. According to the protein sequence and modification type of ribosome biogenesis factor 1, two modified antigen polypeptides A and B are designed. It is detected that the antibody obtained by immunizing animals by using the two polypeptides has high specificity and affinity, and can accurately recognize the acetylation modification form of the 1147th position of BMS1, and avoid recognizing the unmodified form or other modification sites. The antibody is suitable for various immunological detection methods, has high repeatability, low background, has mass production potential, can be industrialized, and is not only used for evaluating the cisplatin resistance in esophageal cancer treatment, but also used for various scenes such as basic research, disease mechanism analysis, biomarker development, drug target screening, and has a wide application range.

The invention discloses a Pt (IV) complex containing a nitrogen donor, a preparation method of the Pt (IV) complex and application of the Pt (IV) complex in preparation of antitumor drugs, and belongs to the field of medicines. A Pt (IV) metal anticancer agent based on an N-containing donor (leflunomide) as an axial ligand for regulating and controlling the drug resistance of the liver cancer by constructing a LOXL3-DHODH axis signal channel is a complex 1 with a chemical structural formula shown as a formula I or a complex 2 with a chemical structural formula shown as a formula II; the complex 1 and the complex 2 have good cytotoxic activity on a cisplatin-resistant hepatoma cell line at a cellular level, and have lower toxicity on normal hepatoma cells than cisplatin. Therefore, the problems of toxicity and drug resistance of traditional platinum drugs can be effectively solved, and the anti-cancer effect of platinum-based drugs is improved. # imgabs0 #